Point72 DIFC Ltd Lowers Position in AngioDynamics, Inc. (NASDAQ:ANGO)

Point72 DIFC Ltd lessened its stake in AngioDynamics, Inc. (NASDAQ:ANGO) by 40.6% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 5,206 shares of the medical instruments supplier’s stock after selling 3,563 shares during the period. Point72 DIFC Ltd’s holdings in AngioDynamics were worth $31,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. AE Wealth Management LLC purchased a new stake in AngioDynamics in the 2nd quarter worth approximately $87,000. State Board of Administration of Florida Retirement System boosted its position in AngioDynamics by 44.1% in the 1st quarter. State Board of Administration of Florida Retirement System now owns 15,627 shares of the medical instruments supplier’s stock worth $92,000 after purchasing an additional 4,780 shares in the last quarter. Bayesian Capital Management LP purchased a new stake in AngioDynamics in the 1st quarter worth approximately $106,000. Concurrent Investment Advisors LLC boosted its position in AngioDynamics by 152.2% in the 2nd quarter. Concurrent Investment Advisors LLC now owns 29,503 shares of the medical instruments supplier’s stock worth $178,000 after purchasing an additional 17,803 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its position in AngioDynamics by 9.1% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 33,772 shares of the medical instruments supplier’s stock worth $199,000 after purchasing an additional 2,821 shares in the last quarter. Hedge funds and other institutional investors own 89.43% of the company’s stock.

AngioDynamics Stock Performance

Shares of ANGO stock opened at $7.66 on Monday. The stock’s fifty day moving average is $7.51 and its two-hundred day moving average is $6.57. The firm has a market capitalization of $306.82 million, a P/E ratio of -1.58 and a beta of 0.65. AngioDynamics, Inc. has a fifty-two week low of $5.26 and a fifty-two week high of $8.25.

AngioDynamics (NASDAQ:ANGO) last announced its quarterly earnings data on Tuesday, July 16th. The medical instruments supplier reported ($0.06) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.11. The company had revenue of $71.00 million for the quarter, compared to analyst estimates of $70.86 million. AngioDynamics had a negative return on equity of 4.91% and a negative net margin of 61.55%. The firm’s revenue for the quarter was down 22.1% on a year-over-year basis. During the same quarter last year, the firm posted $0.02 EPS. On average, equities analysts forecast that AngioDynamics, Inc. will post -0.41 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on ANGO shares. Canaccord Genuity Group decreased their target price on AngioDynamics from $18.00 to $13.00 and set a “buy” rating on the stock in a research report on Wednesday, July 17th. HC Wainwright reiterated a “buy” rating and set a $14.00 target price on shares of AngioDynamics in a research report on Friday, September 20th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $12.25.

AngioDynamics Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.